GlaxoSmithKline plans to work with Britain's Medical Research Council to search for a drug that can be used against the human version of BSE, vCJD. Researchers will screen drug-like molecules in GSK's vast library of compounds in hopes of finding a compound that can enter the brain and bind to the normal prion, preventing it from transforming into an infectious agent.

Full Story:

Related Summaries